Compare NRG & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRG | RMD |
|---|---|---|
| Founded | 1989 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0B | 36.4B |
| IPO Year | 2000 | 1995 |
| Metric | NRG | RMD |
|---|---|---|
| Price | $169.35 | $251.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $187.15 | ★ $292.27 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.04% | 0.96% |
| EPS Growth | ★ 62.56 | 29.59 |
| EPS | 6.78 | ★ 9.77 |
| Revenue | ★ $29,779,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | $7.41 | $9.81 |
| Revenue Next Year | $16.16 | $7.31 |
| P/E Ratio | ★ $25.00 | $25.71 |
| Revenue Growth | 5.91 | ★ 9.36 |
| 52 Week Low | $79.57 | $199.92 |
| 52 Week High | $180.54 | $293.81 |
| Indicator | NRG | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 46.86 |
| Support Level | $160.22 | $237.63 |
| Resistance Level | $168.08 | $254.10 |
| Average True Range (ATR) | 6.96 | 5.46 |
| MACD | 0.22 | 1.03 |
| Stochastic Oscillator | 72.18 | 66.63 |
NRG Energy is one of the largest retail energy providers in the US, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home-services customers. NRG also is one of the largest US independent power producers, with 13 gigawatts of coal, gas, and oil power generation capacity primarily in Texas. The LS Power asset acquisition will add 13 GW of gas-fired power plants mostly in the Eastern US. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.